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Objective. To determine the cost effectiveness of total laparoscopic hysterectomy (TLH) versus total
abdominal hysterectomy (TAH) in early stage endometrial cancer alongside a multicenter randomised
controlled trial (RCT).
Methods. An economic analysis was conducted in 279 patients (TLH n=185; TAH n=94) with early stage
endometrial cancer from a societal perspective, including all relevant costs over a three month time horizon.
Health outcomes were expressed in terms of major complication-free rate and in terms of utility based on
women's response to the EQ-5D. Comparisons of costs per major complication-free patient gained and costs
with utility gain and costs were made, using incremental cost effectiveness ratios.Results. The mean major complication-free rate and median utility scores were comparable between TLH
and TAH at three months. TLH is more costly intraoperatively (Δ$1.129) and less costly postoperatively in-
hospital (Δ$−1.350) compared to TAH. Incremental costs per major complication-free patient were $−52.
Higher cost ($249) were generated while no gains in utility (−0.02) were observed for TLH compared to TAH.
Analysing utility at six weeks, incremental costs per additional point on the EQ-5D scale were $1.617.
Conclusion. TLH is cost effective compared to TAH, based on major complication-free rate as measure of
effect. Along with future cost saving strategies in laparoscopy, TLH is assumed to be cost effective for both
effect measures. Therefore and due to comparable safety, TLH should be recommended as a standard-of-care
surgical procedure in early endometrial cancer.
© 2010 Elsevier Inc. All rights reserved.Introduction
Endometrial cancer is the third most common cancer in women in
Western countries, accounting for 6 to 9% of malignancies in women
with a peak incidence at the age of 55–65 years. The standard
treatment in early stage endometrial cancer patients is totalt Effectiveness Analysis; CI,
Utility Analysis; CVZ, College
e International Federation of
ffect Ratio; RCT, Randomised
Abdominal Hysterectomy and
pic Hysterectomy and Bilateral
ear; ZonMw, Dutch Organiza-
r Groningen, Department of
Groningen, The Netherlands.
rits).
l rights reserved.abdominal hysterectomy and bilateral salpingo-oophorectomy
(TAH) with or without lymphadenectomy through a vertical midline
incision. A good alternative and less invasive approach for patients
with an early stage diseasemight be a total laparoscopic hysterectomy
with bilateral salpingo-oophorectomy (TLH). Three randomised
controlled trials showed that complication rates are similar for both
treatment modalities or resulted in fewer complications for TLH in
this patient group, with a shorter hospital stay, less blood loss, less
pain and a faster resumption of daily activities in favour of
laparoscopy compared to laparotomy [1–3]. The lower complication
rate in the Dutch trial when compared with the American GOG study
and Australian LACE trial is probably due to the fact that patients in
the Netherlands underwent a hysterectomy and bilateral salpingo-
oophorectomy only and not a complete surgical staging including
pelvic and para-aortic lymphadenectomy [3].
The perception that laparoscopic procedures are more costly than
open procedures has been a major reason for the slow acceptance of
advanced (level 3) laparoscopic surgery [4]. Laparoscopy is assumed
77C.B. Bijen et al. / Gynecologic Oncology 121 (2011) 76–82to bemore costly due to longer duration of surgery, expensive surgical
disposable equipment and additional costs in case of conversion to
laparotomy. It is important to know how these cost differences
between TLH and TAH relate to the differences in clinical effects. A
combination of the development of expensive new treatments, the
limited budgets available and the increasing demands on the health
system has led to a need to evaluate the costs in addition to clinical
effects, in order tomake rational decisions regarding the acceptance of
new treatments.
In a recent published review, the beneﬁts of shorter hospital stay
after laparoscopy seemed to compensate for the increased procedure
related costs [5]. Thus if laparoscopic hysterectomy has beneﬁts for
the patients over laparotomy, it might be a promising alternative.
However, given the methodological impediments of the majority of
studies included in this review, no ﬁrm conclusions could be drawn.
Importantly, randomised controlled trials are the most rigorous way
of determining the cost effectiveness of a treatment avoiding all sorts
of bias [6]. Therefore a broader, societal perspective is needed,
including all relevant costs and clinical effects for determining
implications for practice. The aim of this study is to evaluate the
cost effectiveness of the two surgical approaches (TLH versus TAH),
carried out alongside a multicenter randomised controlled trial,
complying with all guidelines [7,8].
Methods
Study design
A detailed description of the study protocol has been reported
elsewhere [9] and is summarized here brieﬂy. This multi-center
prospective randomised clinical phase three trial included 26
gynaecologists in 21 centers in the Netherlands. The gynaecological
surgeons were allowed to participate in the study only after
achieving sufﬁcient laparoscopic skills for performing a TLH, accord-
ing to a predeﬁned assessment [9]. We included women with
histologically proven endometrioid adenocarcinoma, grade 1 or 2, or
complex atypical hyperplasia, clinically conﬁned to the uterine
corpus. Exclusion criteria were any non-endometrioid adenocarci-
noma histological types, uterine size larger than that expected at
twelve weeks pregnancy and cardiopulmonary contraindications for
laparoscopy or laparotomy. After given informed consent, eligible
patients were randomised in a 2:1 allocation to receive TLH or TAH.
Amongst 283 randomised patients, 187 were assigned to the TLH
group and 96 to the TAH group during the study period of 23 months.
In each arm two patients were randomised, although it was known
before randomisation that they did not fulﬁl the inclusion criteria.
These patients were not included in the intention-to-treat analysis
(Fig. 1) [1]. The study coordinator had no access to data during the
study. The study was conducted according to the principles of the
Declaration of Helsinki and in accordance with the Medical Research
Involving Human Subjects Act (WMO). Ethics approval was obtained
from local research ethics committees. Patients were informed that
there was no proven advantage for either TLH or TAH in early
endometrial cancer patients so far, and therefore this study was
performed. All women gave written, informed consent before




An economic evaluation was conducted alongside the randomised
clinical trial and performed from a societal perspective, meaning all
relevant costs both inside and outside the hospital were included. A
cost effectiveness analysis (CEA) was undertaken to evaluate the
balance between costs and effects of both treatment modalities overa 3 months time horizon. The CEA depicts the additional costs per
major complication-free patient that need to be invested in the
situation that TAH is replaced by TLH. In addition, a cost utility
analysis (CUA) was undertaken to evaluate the balance between
costs and utility of both surgical techniques. The CUA depicts the
additional costs per extra point on the utility scale. Finally, cost
effectiveness planes were constructed depicting 5000 bootstrap
replications of the trial data. From these estimates, a conﬁdence
interval and an acceptability curve were generated, representing the
probability that an intervention (TLH) is most effective over a range
of thresholds [8,10,11].
Assessment of cost
Resource use data included procedure costs (time, housing,
equipment, disposables, overhead), hospital stay and costs incurred
during the postoperative period (Table 1). A case record form
(CRF) was used to gather these in-hospital medical costs. Cost
components were valued according to standard Dutch guidelines
for economic evaluation (College Voor Zorgverzekeringen, CVZ
2004). The price level used was that of 2008 and costs were
calculated in Euros (€) and converted to US Dollars ($) at the
conversion rate of 31-12-2008. Actual costs were estimated for the
laparotomy and laparoscopy (Table 1). The patient questionnaire
was used to collect information on costs of additional home care,
professional as well as informal. Informal care was valued by using
shadow prices (Table 1). Because of the composition of the patient
group, characterized by women with a median age of 63 years
(Table 2), productivity losses were not included in the economic
evaluation. Since no differences regarding complication rate and
quality of life were expected between the two study arms after
three months, a time horizon of three months was considered to
be sufﬁcient for evaluation of costs. As a consequence, discounting
was not applied.
Assessment of effects
Our primary measure of effect was major complication-free rate.
Data and details on patients with a major complication were
published previously [1]. All complications were recorded intra- and
postoperatively until three months after surgery for each patient.
After completing of inclusion complication data were re-checked on
site for possible inaccuracies or incompleteness. Data on major
complication-free rate was complete for all cases. The secondary
measure of effect was utility, and was added, to increase the
comparability between our results and the results from other studies.
Utility reﬂects differences in health-related quality of life based on
women's response to the Euroqol-5D (EQ-5D) questionnaire at
baseline and up to three time points after surgery (6 weeks, 3 months
and 6 months) [1,12]. For a subgroup of 25 patients EQ-5D
questionnaires were sent one year after surgery. Scores were
calculated using Dolans algorithm, based on the preferences elicited
from the general UK population [13]. No imputation techniques were
used since baseline characteristics and health outcomes did not differ
between completers and non-completers.
Sensitivity analysis
A sensitivity analysis was conducted to assess how differential
costs would have changed if all laparoscopic procedures had been
undertaken with a cheaper disposable vaginal tube (i.e., decreasing
the price of the Mc Cartney tube by 50%) and shortening of the
hospital stay with one day in the laparoscopy group, based on an
expert opinion of evolving laparoscopic practice. In this scenario we
assumed that there would be no impact on health outcomes from this
change in policy. In addition, a sensitivity analysis was performed
with the effect measure utility (EQ-5D) and total costs at six weeks
and was compared with a previous literature.
Fig. 1. Flowchart patients.
78 C.B. Bijen et al. / Gynecologic Oncology 121 (2011) 76–82Statistical analysis
All patients were analysed on an intention-to-treat basis.
Descriptive data are reported as mean (standard deviation), 95%
conﬁdence interval (CI), median and range, or number of patients
and percentage. For clinical and demographical data, a comparison
between groups for categorical variables was made by χ2 test or the
Fisher exact test when appropriate. In other situations, nonpara-
metric analysis was performed: the Mann–Whitney U test was used
to test differences between groups. The P-values b0.05 were
considered to indicate statistical signiﬁcance (2-tailed test). Analyseswere performed using Microsoft Ofﬁce Excel (2003) and the SPSS




Baseline characteristics were equally distributed between treat-
ment arms in the intention-to-treat-analysis (Table 2). The median
age was 63 years (39 to 89) and the median BMI was 29 kg/m2 (17 to
Table 1
Resources and quantity unit per treatment arm.
Item Unit Price Method TLH mean (SD)a TAH mean (SD) Difference
Operative procedure 1653 (486) 524 (238) 1129
Operating time (personnel) Per minute 4404 CVZ 2004 524 (172) 362 (165) 162
Disposables Per set 1410 Cost price 894 (412) 0 (0) 894
Overhead/housing OK time 10%/35% HVK 2004: 64–66 235 (78) 162 (73) 73
Hospital stay 1656 (1402) 3007 (1656) −1350
General hospital/
University medical center (3:1) Per day 562.83 HvK 2004: 70–72
Additional homecare 1558 (2718) 1511 (2126) 47
Homecare (housework) Per hour 40.43 HvK 2004: 94–95 279 (925) 368 (761) −89
Homecare (nursing) Per hour 61.16 HvK 2004: 94–95 826 (1842) 732 (1387) 94
Time costs informal care Per hour 12.56 HvK 2004: 107–111 420 (902) 340 (593) 80
Home served meals Per time 9.16 Mean cost price 32 (151) 73 (251) −41
a SD=standard deviation.
79C.B. Bijen et al. / Gynecologic Oncology 121 (2011) 76–8255). In total, 117 (42.2%) patients were obese (NBMI 30 kg/m2). Co-
morbidity (chronic disease and/or previous malignancy) was
reported in nearly 60% of included patients. Based on the ﬁnal
pathology report, themajority (84.2%) had International Federation of
Gynaecologists & Obstetricians (FIGO) stage I endometrioid adeno-
carcinoma or complex atypical hyperplasia.Cost comparison
The cost components used for the cost evaluation with accompa-
nying quantity units are depicted in Table 1. A mean difference of
$1.129 in surgical procedure costs reﬂects the signiﬁcant longer
duration of surgery in the TLHarm(115 min; 35 to 267) versus the TAH
arm (71 min; 31 to 239) (pb0.001) (not in Table) and the extra costs of
the use of disposableswith laparoscopy. The total costs for the duration
of hospital stay differed with $1.350 in favour of laparoscopy. Patients
treated by laparoscopy had a shorter (2 days; 1 to 25) hospital stay
after surgery than patients treated by laparotomy (5 days; 3 to 32)
(pb0.001) (not in Table). Information about additional home carewas
completed in 72.0% of the patients. Patients treated by laparoscopy
experienced more hours of additional home care than after a
laparotomy, reﬂecting the fact that due to an earlier discharge for
laparoscopy patients relatively longer home care (nursing) is needed.Table 2
Baseline characteristics of patients (N (%)a).
Baseline Overall N=279 TLH N=185 TAH N=94
Median age (range) years 63 (39–89) 62 (40–89) 63 (39–86)
BMI (median; range) kg/m2 29 (17–55) 29 (17–55) 28 (19–48)




165 (59.1) 107 (57.8) 58 (61.7)
Previous abdominal surgery 78 (28.0) 55 (29.7) 23 (24.5)
Histological subtype
No dysplasia/malignancy 12 (4.3) 11 (6.0) 1 (1.1)
Complex atypical hyperplasia 31 (11.2) 24 (13.0) 7 (7.4)
Endometrioid adenocarcinoma 230 (82.7) 147 (79.9) 83 (88.3)
Papillary adenocarcinoma 3 (1.1) 1 (0.5) 2 (2.1)
Sarcoma 2 (0.7) 1 (0.5) 1 (1.1)
(1 missing)
FIGOb stage
I 205 (87.2) 130 (87.2) 75 (87.2)
II 23 (9.8) 15 (10.1) 8 (9.3)
III 4 (1.7) 2 (1.3) 2 (2.3)
IV 3 (1.3) 2 (1.3) 1 (1.2)
(1 missing)
a Unless otherwise speciﬁed.
b International Federation of Gynaecologists & Obstetricians.Health outcomes
Therewas no difference observed in themeanmajor complication-
free rate between TLH (85.4%) and TAH (85.1%) (p=0.95) [1]. Data on
major complication-free rate was complete for all cases. At six weeks,
median EQ-5D utility scoreswere 0.81 (–0.2 to 1.0) for TLH versus 0.80
(0.3 to 1.0) for TAH. At three months, median scores for TLHwere 0.81
(–0.4 to 1.0) compared to 0.85 (0.6 to 1.0) for TAH. Median Quality
adjusted life years (QALYs) were comparable in both arms at three
months, 0.19 (–0.06 to 0.23) for TLH and 0.19 (0.10 to 0.23) for TAH,
adjusted for baseline (not in Table). The overall response rate on the
questionnaires was 90% (range 88% to 93%) at various assessment
points. No signiﬁcant differences in compliance were observed
between the treatment arms. Data about EQ-5D was complete in 83%
of patients. Four patients died (grade 5)within sixweeks after surgery;
three of these (3/185; 1·6%) died after TLH and one after TAH (1/94;
1·1%) (Fig. 1). Two patients died of progressivemetastatic disease, one
patient died most probably due to a pulmonary embolism ﬁve days
after surgery, and one died because of progressive hypoxia leading to a
hypoxic coma, with already existing cardiopulmonary problems.
Cost effectiveness
With a mean difference of $−8 in costs and a mean difference of
0.16% inmajor complication-free rate, the incremental cost effect ratio
(ICER) generated is $−52 (−988 to 1.106) for laparoscopy, based on
the bootstrap simulations (TLH N=142; TAH N=70).
From the bootstrapped cost effectiveness plane (Fig. 2A) it can be
seen that the ICER is located at the south eastern quadrant. The
acceptability curve (Fig. 2B) showed that the probability that TLH is
more cost effective in terms of major complications than TAH is never
above 53%. A mean difference of $249 in costs and a mean difference
of −0.02 in utilities generate an ICER of $−15.604 for laparoscopy,
based on the bootstrap simulations (TLH N=134; TAH N=67). This
ICER is located in the NorthWest quadrant (Fig. 3A). The acceptability
curve (Fig. 3B) showed that the probability that TLH is more cost
effective than TAH in terms of utilities is never above 31%.
Sensitivity analysis
In case of reducing disposable costs and duration of hospital stay in
the TLH arm, the mean difference (TLH–TAH) in costs was increased
to $−681 in favour of TLH and the ICER for laparoscopy to $−4.229
(−3.138 to 1.837) (Fig. 4A) with major complication-free rate as the
measure of effect. For the CUA, the mean difference in costs was
increased to $−455 in favour of TLH and the ICER for laparoscopy
to $28.527 (−228.345 to 240.075) (Fig. 4B). In case of analysing utility
at six weeks instead of three months (Fig. 4C), the bootstrapped
samples shifted to the eastern quadrants, meaningmore effects (0.05)
Fig. 2. A Cost effectiveness planes for major complication-free rate; B acceptability
curve for major complication-free rate. * = scatterplot of the estimated (joint density)
of incremental costs and incremental effects of TAH versus TLH, based on 5000
bootstrap re-samples of the original trial data. The main dot represents the base
estimate of incremental costs and effects, all other individual dots represent bootstrap
replications. The two quadrants right from the Y axis represent the replications were
TLH is more effective than TAH, and vice versa for left from the Y axis. Dots below the X
axis represent lower costs of TLH versus TAH and vice versa for under the X axis.
Fig. 3. A Cost effectiveness planes for utility; B acceptability curve for utility.
Fig. 4. A for major complication-free rate (reducing costs); B for utility (reducing costs);
and C for utility (at 6 weeks).
80 C.B. Bijen et al. / Gynecologic Oncology 121 (2011) 76–82for laparoscopy with lower costs ($−100), generating an ICER of
$−1.617 (−38.709 to 25.793).
Discussion
From this cost effectiveness analysis it can be concluded that TLH
appears to be preferable over the conventional approach by TAH as an
amount of $52 will be saved per additional major complication-free
patient. The higher operative procedure costs of TLH were compen-
sated by the lower costs for hospital stay when compared to TAH.
Major complication-free rate was higher and utility scores were lower
in the TLH group when compared to the TAH group. With respect to
utility, higher costs were generated while no gains in utility were
observed for TLH compared to TAH.
To our knowledge, this is the ﬁrst multi center randomised study
comparing cost effectiveness of laparoscopy and laparotomy in early
stage endometrial cancer patients. The fact that TLH is considered as
being preferable, based on the major complication-free rate as the
measure of effect, is consistent with a recently published review [5]. In
this review, comparing costs and cost effectiveness between laparo-
scopic and abdominal hysterectomies in twelve prospective con-
trolled trials [14–25], laparoscopic hysterectomy pointed in the
direction of cost effectiveness due to a lower major complication
rate, with higher costs in the laparoscopy group when compared to
laparotomy. However, all studies were performed in patients with a
benign indication for the removal of the uterus, and used different
variants of laparoscopic techniques. Besides, due to ﬂexibility in
design, deﬁnitions, outcomes, and analytical modes for costs in the
previous studies, a rigorously set up, well-designed RCT is a
prerequisite to evaluate the cost effectiveness of the two surgical
81C.B. Bijen et al. / Gynecologic Oncology 121 (2011) 76–82approaches (TLH versus TAH) in early endometrial cancer patients
and complies with all guidelines for costs studies.
If all laparoscopic procedures had been undertaken with cheaper
disposables because of expected changes in cost price, TLH would be
considered more cost effective. This was illustrated in Figs. 4A and B,
in which all points shifted to the lower quadrants of the planes when
compared to Figs. 2 and 3. The same phenomenon was seen when
utility six weeks after surgery was taken into account instead of three
months. This time horizon was chosen to compare the utility scores
with a previous RCT by Sculpher et al. on laparoscopy in patients with
a benign indication for the removal of the uterus [21]. The differences
in median utility scores between the two surgical techniques was
comparable at six weeks, but both utility scores were lower in our
study (TLH: 0.81 versus TAH: 0.80) when compared to the study of
Sculpher et al. (TLH: 0.87 versus TAH: 0.88). The fact that all patients
in our study are entrusted with a malignant disease might have had
more impact on the quality of life than the surgical technique itself.
The limitations of our study are the short follow-up of three
months and consequently not taking survival into account as an effect
measure. Because of this three month period, utility is taken as the
effect measure instead of the Quality Adjusted Life Years. The time
horizon of three months was chosen since no differences regarding
complications and quality of life were expected between the two
study arms after three months. A clinical signiﬁcant difference in
prognostic impacts between the two surgical techniques on patients
with early endometrial cancer is not expected. From the recent
preliminary data it can be concluded that patients staged by
laparoscopy or laparotomy had similar recurrence rates and patterns
and an estimated three-year survival of about 90% [26,27].
Furthermore, in a random sample of twenty-ﬁve patients included
in the trial, we analysed costs and cost effectiveness and found no
differences in costs and effects between treatment groups at twelve
months. However, these results need to be interpreted carefully given
the small number of patients in that pilot.
We used a societal perspective to estimate the costs of both
surgical procedures. Any differential impact of the procedures on time
away from the usual activities, including paid employment, might be
reﬂected in differential productivity costs. This randomised trial
collected data on the rate of returning to paid or volunteer work.
These showed that the rate of returning to work at six weeks after
surgery did not differ between patients in the TLH (37/167; 22.2%)
and TAH (22/82;26.8%) groups (p=0.42) [1]. The fact that the return
rates were comparable and reported in small groups due to a high
median age of patients would not have altered the relative cost
effectiveness of these two procedures.
The results of this randomised study on laparoscopy versus
laparotomy for the early stage endometrial cancer can be used to
guide further implementation of laparoscopic hysterectomy. In our
published RCT with major complication rate as the primary outcome
measure, we concluded that there is no evidence of a lower
complication rate in laparoscopy when compared to laparotomy in
patients with the early stage endometrial cancer. Nevertheless,
laparoscopy has the advantage of a shorter hospital stay, less pain
after surgery and a quicker resumption of daily activities [1]. The
question rises, should we implement this surgical technique as the
standard approach for this patient category? Since safety was
comparable between both interventions, the treatment related
outcome and cost effectiveness will become decisive. In the here
presented analysis, we concluded that TLH is cost effective compared
to TAH, based on major complication-free patients as a measure of
effect. Although the laparoscopic technique itself requires attention,
the quality of the implementation of the laparoscopic intervention
depends not only on the surgeon but also on the surgical environment,
including the operating team, and the preoperative and postoperative
care. Moreover, further development, experience and improvement of
laparoscopic equipment are to be expected when compared to theconventional approach. This advancement of the laparoscopic equip-
ment and techniques together with optimizing the efﬁciency in
surgical teams and post operative caremight lead to the improvement
of the surgical outcome in laparoscopy patients in the future. This
prospect of a shorter hospital staywas included in a sensitivity analysis,
resulting in an evenmore cost effective approach. Alongwith potential
cost saving strategies in laparoscopic surgical equipment, TLH is cost
effective and due to comparable safety should be recommended as a
standard-of-care surgical approach for the early stage endometrial
cancer. Based on the results of the study presented here and this future
perspective, policymakersmight be able tomake a rational decision for
acceptance of this new laparoscopic treatment for the early stage
endometrial cancer with improved health gain and lower costs.
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